Indaptus Therapeutics (NASDAQ:INDP) Stock Price Up 22.4% – What’s Next?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) rose 22.4% during mid-day trading on Wednesday . The company traded as high as $4.46 and last traded at $4.5540. Approximately 404,040 shares were traded during mid-day trading, a decline of 29% from the average daily volume of 565,461 shares. The stock had previously closed at $3.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Indaptus Therapeutics presently has a consensus rating of “Sell”.

Indaptus Therapeutics Trading Up 23.7%

The firm has a market capitalization of $521.02 million, a price-to-earnings ratio of -0.30 and a beta of 1.25. The company’s 50 day moving average is $2.35 and its 200-day moving average is $2.26.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.